Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome.
Silvestri E, Bitossi A, Bettiol A, Emmi G, Urban ML, Mattioli I, Di Scala G, Bacherini D, Lopalco G, Venerito V, Iannone F, Vitale A, Tosi GM, Rizzo S, Fabiani C, Cantarini L, Virgili G, Vannozzi L, Prisco D.
Silvestri E, et al. Among authors: rizzo s.
Inflammopharmacology. 2020 Jun;28(3):711-718. doi: 10.1007/s10787-020-00697-4. Epub 2020 Mar 10.
Inflammopharmacology. 2020.
PMID: 32157555